One Medicals new GLP-1 programme could reset access and cost expectations for Canadian plan sponsors Amazon is turning obesity treatment into a highly convenient, subscription-style service, a shift that could reshape expectations around access and cost for GLP-1 drugs that Canadian plan sponsors already see on the horizon
Available Anti-Obesity Medications Several drugs are currently approved for the treatment of obesity, including phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and two GLP-1 receptor agonists liraglutide 3.0mg and semaglutide 2.4mg [21, 22]
F., Couve, E., Mannervik, B., Paris, I., & Segura-Aguilar, J
Ongoing monitoring of adverse events continues, as lawsuits related to device fractures proceed in court